This study is accepting new patients by invitation only
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
Summary
- Eligibility
- for males (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Perry B. Shieh, MD, PhD

Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Perry B. Shieh, MD, PhD
HS Clinical Professor, Neurology, Medicine. Authored (or co-authored) 91 research publications
Details
- Status
- accepting new patients by invitation only
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Sarepta Therapeutics, Inc.
- Links
- Sign up for this study
- ID
- NCT05967351
- Phase
- Phase 3 Duchenne Muscular Dystrophy Research Study
- Study Type
- Interventional
- Participants
- Expecting 400 study participants
- Last Updated